Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease

International Journal of Obesity

Volumn 41, Issue 8, 2017, Pages 1207-1213

  Lefere, S ^a   Van De Velde, F ^a   Devisscher, L ^a   Bekaert, M ^a   Raevens, S ^a   Verhelst, X ^a   Van Nieuwenhove, Y ^a   Praet, M ^a   Hoorens, A ^a   Van Steenkiste, C ^a,b   Van Vlierberghe, H ^a   Lapauw, B ^a   Geerts, A ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Maria Middelares Hospital   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; ENDOGLIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACENTAL GROWTH FACTOR; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN D; BIOLOGICAL MARKER;

ADULT; ARTICLE; BARIATRIC SURGERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION; HUMAN; HYPERTENSION; INTRAPERITONEAL FAT; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; OBESITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AREA UNDER THE CURVE; BLOOD; COMPLICATION; DISEASE EXACERBATION; DYSLIPIDEMIA; GENE EXPRESSION REGULATION; INSULIN RESISTANCE; LIVER CIRRHOSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; UPREGULATION; VALIDATION STUDY;

ADULT; AREA UNDER CURVE; BARIATRIC SURGERY; BIOMARKERS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DYSLIPIDEMIAS; GENE EXPRESSION REGULATION; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 85026922800     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2017.102     Document Type: Article

References (47)

1. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2: 901-910.
2. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 2015; 47: 181-190.
3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.
4. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547-1554.
5. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatchar-oenwitthaya P et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389-397.e10.
6. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohe-patitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
7. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402.
8. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013; 58: 1007-1019.
9. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-460.
10. McPherson S, Anstee QM, Henderson E, Day CP, Burt AD. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol 2013; 25: 652-658.
11. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 42: 473-480.
12. Long MT, Wang N, Larson MG, Mitchell GF, Palmisano J, Vasan RS et al. Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study. Arterioscler Thromb Vasc Biol 2015; 35: 1284-1291.
13. Kasumov T, Edmison JM, Dasarathy S, Bennett C, Lopez R, Kalhan SC. Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism 2011; 60: 776-781.
14. Verrijken A, Francque S, Mertens I, Prawitt J, Caron S, Hubens G et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2014; 59: 121-129.
15. Kitade M, Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y et al. Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of nonalcoholic steatohepatitis. World J Gastroenterol 2009; 15: 5193-5199.
16. Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K et al. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepa-titis in rats. Hepatology 2006; 44: 983-991.
17. Coulon S, Legry V, Heindryckx F, Van Steenkiste C, Casteleyn C, Olievier K et al. Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology 2013; 57: 1793-1805.
18. Francque S, Laleman W, Verbeke L, Van Steenkiste C, Casteleyn C, Kwanten W et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Invest 2012; 92: 1428-1439.
19. Lefere S, Van Steenkiste C, Verhelst X, Van Vlierberghe H, Devisscher L, Geerts A. Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease. Cell Mol Life Sci 2016; 73: 3419-3431.
20. Pasarin M, Abraldes JG, Rodriguez-Vilarrupla A, La Mura V, Garcia-Pagan JC, Bosch J. Insulin resistance and liver microcirculation in a rat model of early NAFLD. J Hepatol 2011; 55: 1095-1102.
21. Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol 2016; 65: 425-443.
22. Bekaert M, Ouwens DM, Horbelt T, Van de Velde F, Fahlbusch P, Herzfeld de Wiza D et al. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity. Obesity 2016; 24: 2544-2552.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
24. American Diabetes Association. Standards of Medical Care in Diabetes-2016. Diabetes Care 2016; 39 (Suppl 1): S1-112.
25. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.
26. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
27. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
28. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012; 32: 3-13.
29. Bedossa P, Consortium FP. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014; 60: 565-575.
30. Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohe-patitis and fibrosis. Hepatology 2012; 56: 943-951.
31. du Plessis J, van Pelt J, Korf H, Mathieu C, van der Schueren B, Lannoo M et al. Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 635-648.e14.
32. Sung HK, Doh KO, Son JE, Park JG, Bae Y, Choi S et al. Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell Metab 2013; 17: 61-72.
33. Ratziu V. Novel pharmacotherapy options for NASH. Dig Dis Sci 2016; 61: 1398-1405.
34. Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease-the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014; 39: 254-269.
35. Sun K, Wernstedt Asterholm I, Kusminski CM, Bueno AC, Wang ZV, Pollard JW et al. Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci USA 2012; 109: 5874-5879.
36. Flemming S, Burkard N, Renschler M, Vielmuth F, Meir M, Schick MA et al. Soluble VE-cadherin is involved in endothelial barrier breakdown in systemic inflammation and sepsis. Cardiovasc Res 2015; 107: 32-44.
37. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2292-2301.
38. Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 2012; 59: 442-449.
39. Dewerchin M, Carmeliet P. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med 2012; 2: a011056.
40. Tarantino G, Conca P, Pasanisi F, Ariello M, Mastrolia M, Arena A et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 2009; 21: 504-511.
41. Yilmaz Y, Yonal O, Kurt R, Alahdab YO, Ozdogan O, Celikel CA et al. Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease. Arch Med Res 2011; 42: 38-43.
42. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13: 837-844.
43. Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B et al. Limited value of plasma cytokeratin-18 as a biomarkerfor NASH and fibrosis in patients with nonalcoholic fatty liver disease. J Hepatol 2014; 60: 167-174.
44. Yoshimura K, Okanoue T, Ebise H, Iwasaki T, Mizuno M, Shima T et al. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. Hepatology 2016; 63: 462-473.
45. Raevens S, Coulon S, Van Steenkiste C, Colman R, Verhelst X, Van Vlierberghe H et al. Role of angiogenic factors/cell adhesion markers in serum of cirrhotic patients with hepatopulmonary syndrome. Liver Int 2015; 35: 1499-1507.
46. Lo Iacono O, Rincon D, Hernando A, Ripoll C, Catalina MV, Salcedo M et al. Serum levels of soluble vascular cell adhesion molecule are related to hyperdynamic circulation in patients with liver cirrhosis. Liver Int 2008; 28: 1129-1135.
47. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185: 67-76.